A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener ADP Assay
Analysis of drug–target residence times during drug development can result in improved efficacy, increased therapeutic window, and reduced side effects. Residence time can be estimated as the reciprocal of the dissociation rate (koff) of an inhibitor from its target. The traditional methods for meas...
Saved in:
Published in | SLAS discovery Vol. 22; no. 7; pp. 915 - 922 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Los Angeles, CA
SAGE Publications
01.08.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Analysis of drug–target residence times during drug development can result in improved efficacy, increased therapeutic window, and reduced side effects. Residence time can be estimated as the reciprocal of the dissociation rate (koff) of an inhibitor from its target. The traditional methods for measuring koff require synthesis of labeled ligands or low-throughput label-free methods. To provide an alternative that is better suited to an automated high-throughput screening (HTS) environment, we adapted a classic “jump dilution” catalytic assay method for determination of koff values for kinase inhibitor drugs. We used the Transcreener ADP2 Kinase assay as a universal, homogenous method to monitor the recovery of kinase activity as the drugs dissociated from preformed inhibitor–kinase complexes. We measured residence times for several drugs that bind the epidermal growth factor receptor (EGFR), ABL1, and Aurora kinases and found that the rank ordering of inhibitor koff values correlated with literature values determined using ligand binding assays. Moreover, very similar results were obtained using the Transcreener assay with fluorescence polarization (FP), fluorescence intensity (FI), and time-resolved Förster resonance energy transfer (TR-FRET) detection modes. This HTS-compatible, generic assay method should facilitate the use of residence time as a parameter for compound prioritization and optimization early in kinase drug discovery programs. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2472-5552 2472-5560 |
DOI: | 10.1177/2472555217695080 |